home-slider-01
4 Generations of Knowledge
3 Decades of Investing in Innovation
usvp-home3
We Help Entrepreneurs Build Market Leaders
usvp-home2

Focused on Early Stage IT and Healthcare Investments

usvp-home4

A Network of 400 Companies and 4,000 Executives

Play Video

USVP IN NUMBERS

$3.9B

Total Invested

493

Companies

88

IPOs

NEWS

What Palo Alto Networks Won’t Tell You About Its New SASE Service
November 22, 2019

What Palo Alto Networks Won’t Tell You About Its New SASE Service

What Palo Alto Networks Won’t Tell You About Its New SASE Service
Network WorldPress
eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies
November 5, 2019

eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies

eFFECTOR Therapeutics Initiates Phase 1/2 Safety and Efficacy Study of Zotatifin (eFT226) in Patients with Advanced Solid Tumor Malignancies
GlobeNewswirePress
Okami Medical Announces Major Milestones: FDA 510(k) Clearance and Key Patent for the LOBO Vascular Occluder
November 4, 2019

Okami Medical Announces Major Milestones: FDA 510(k) Clearance and Key Patent for the LOBO Vascular Occluder

Okami Medical Announces Major Milestones: FDA 510(k) Clearance and Key Patent for the LOBO Vascular Occluder
Okami MedicalPress